NASDAQ: ARWR · Biotechnology
Arrowhead Pharmaceuticals (ARWR) fair value and price range
As of 15 Nov 2026, Faircurve's model values Arrowhead Pharmaceuticals (ARWR) at $53.67 a share. The stock last closed at $44.21, which puts the model's fair value 21.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Arrowhead Pharmaceuticals, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 15 Nov 2026 moved the fair value from $54.23 to $53.67 (-1.0%). The multiple the model anchors on moved, lowering the fair value: most of the move.
What the model makes of itThe price of $44.21 is 21.4% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 4 Feb 2027. Options prices imply a move of about 20% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give ARWR?
The calibrated range for ARWR over 63 trading days is $35.37 to $55.88. It sits around the last close, and its width comes from the volatility that ARWR's own options imply (68% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $31.17 to $85.50. In 58% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 15 Nov 2026
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company based in Pasadena, California, founded in 1989. It works on innovative treatments for complex and challenging-to-treat diseases within the United States.
Faircurve's model valued Arrowhead Pharmaceuticals (ARWR) on 15 Nov 2026 and found a fair value of $53.67 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $54.23, so the model's fair value moved -1.0%. In the model's own words, "The multiple the model anchors on moved, lowering the fair value: most of the move." The calibrated range over 63 trading days runs from $38.62 to $59.74. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.
Arrowhead's overall quality score is 36 out of 100, a composite of six quality factors scored against comparable companies. Earnings quality scores 100. Stability scores 0, with EBITDA margin downside volatility at 5634.7 pts over five years. Growth quality scores 3, with trailing revenue growth at -45.6%. The model compares Arrowhead with Protagonist Therapeutics, Inc. (PTGX), TG Therapeutics, Inc. (TGTX) and BioMarin Pharmaceutical Inc. (BMRN), each with its own fair value on the site.
Written from the figures on this page for the 15 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does ARWR report earnings, and how has the stock reacted?
Arrowhead Pharmaceuticals's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 15.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ARWR's 30 day implied volatility works out to about 19.5% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ARWR's last 8 reports, ignoring direction, was 5.9%.
What the options market has priced for a month's move in ARWR
How does ARWR score on business quality?
Arrowhead Pharmaceuticals's overall quality score is 36 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 5 | -71.6%ROIC | |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 3 | -45.6%Revenue growth, trailing | |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 72 | 0.0%Net buybacks / market value | |
| Balance sheetNet debt to EBITDA and interest coverage. | 70 | -1.49xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 5634.7 ptsEBITDA margin downside volatility, 5y |
How does ARWR compare with similar companies?
The companies in biotechnology closest to Arrowhead Pharmaceuticals in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $301.71 | $282.99 | -6.2% | Low evidence grade |
| CYTK Cytokinetics, Incorporated | $53.17 | $63.03 | +18.5% | Low evidence grade |
| PTGX Protagonist Therapeutics, Inc. | $124.83 | $104.97 | -15.9% | Overvalued |
| PTCT PTC Therapeutics, Inc. | $60.97 | $74.62 | +22.4% | Low evidence grade |
| KRYS Krystal Biotech, Inc. | $297.90 | $352.42 | +18.3% | Low evidence grade |
| TGTX TG Therapeutics, Inc. | $62.76 | $75.36 | +20.1% | Undervalued |
| BMRN BioMarin Pharmaceutical Inc. | $57.99 | $69.09 | +19.1% | Undervalued |
| HALO Halozyme Therapeutics, Inc. | $96.50 | $111.93 | +16.0% | Low evidence grade |
What the comparable companies' multiples alone would give for ARWR, the peer-implied price, is $131.50 a share on this run. The fair value weighs that against the company's own multiple.
Arrowhead Pharmaceuticals at a glance
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States.
- Market value
- $6.7B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $337M
- Consensus revenue growth, next fiscal year
- -32.1%
- Analysts with estimates
- 12
- Beta to the US market
- 1.27
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Arrowhead Pharmaceuticals on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for ARWR was $54.23. As of 15 Nov 2026 it is $53.67, a change of -1.0%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Arrowhead Pharmaceuticals's valuation
Is Arrowhead Pharmaceuticals stock undervalued or overvalued?
Faircurve's model puts ARWR's fair value at $53.67 a share against a last close of $44.21, as of 15 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is ARWR's fair value?
$53.67 a share as of 15 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $31.17 to $85.50.
What price range does the model give ARWR?
$35.37 to $55.88 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Arrowhead Pharmaceuticals report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has ARWR moved on past earnings reports?
Across its last 8 reports the median two session move was 5.9%, ignoring direction. The largest was +39.2% around the report of 26 Nov 2024.
How confident is the model in this valuation?
The model's evidence grade for ARWR is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on ARWR
The model holds no idea open on ARWR today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ARWR with their outcomes. A free account is enough.